Evolus (EOLS) Other financing activities (2017 - 2026)

Evolus (EOLS) reported Other financing activities of $484000.0 for Q1 2026, up 1373.68% quarter-over-quarter from -$38000.0 in Q3 2023.

Evolus (EOLS) Other financing activities (2017 - 2026) Analysis & Trends

Evolus has reported Other financing activities for 6 years, with the latest figure at $484000.0 in Q1 2026.

For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $484000.0; the trailing twelve-month figure through Mar 2026 stood at $484000.0 (changed N/A YoY), and the FY2024 full-year result was $248000.0, changed N/A from the prior year.
Other financing activities for Q1 2026 stood at $484000.0, up from -$38000.0 in the prior quarter.
The five-year high for Other financing activities was $500000.0 in Q4 2022, with the low at -$38000.0 in Q3 2023.
Historically, Other financing activities has averaged $315333.3 across 3 years, with a median of $484000.0 in 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Evolus	437.40 Mn	387.61 Mn	48.90 Mn

Download Data